
    
      This study is a prospective multicenter single-arm phase II clinical trial. Rectal cancer
      patients with cT3 stage will receive neoadjuvant chemoradiotherapy, and be evaluated the
      response of the tumor in 6 to 10 weeks after completion of neoadjuvant chemoradiotherapy. For
      those who have good response (ycT0-1) will underwent transanal local excision under the
      patients' agree.
    
  